GINA Stepwise Asthma Management
Overview of the Stepwise Approach
The Global Initiative for Asthma (GINA) 2024 guidelines recommend a two-track stepwise approach, with Track 1 (preferred) using as-needed low-dose ICS-formoterol as the reliever at all steps, and Track 2 (alternative) using as-needed SABA as the reliever. 1
The fundamental principle is to step up therapy when asthma is inadequately controlled and step down when well-controlled for at least 3 consecutive months. 2, 1
Track 1 (Preferred): ICS-Formoterol as Reliever
Step 1 – Mild Intermittent Asthma
- As-needed low-dose ICS-formoterol only (no daily maintenance therapy) 1
- This approach reduces severe exacerbations by ≥60% compared with SABA alone 3
- Currently off-label; clinical data available only for budesonide-formoterol or beclomethasone-formoterol 1
Step 2 – Mild Persistent Asthma
- As-needed low-dose ICS-formoterol only (no daily maintenance therapy) 1
- This provides similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA 3
Step 3 – Moderate Persistent Asthma
- Daily low-dose ICS-LABA plus as-needed low-dose ICS-formoterol (MART regimen) 1
- MART provides greater or equal asthma control compared with fixed-dose ICS/LABA plus SABA, with lower overall ICS doses 4
Step 4 – Severe Persistent Asthma
- Daily medium-dose ICS-LABA plus as-needed low-dose ICS-formoterol (MART regimen) 1
- Consider adding tiotropium (LAMA) for patients ≥12 years with uncontrolled asthma 1
- Specialist consultation recommended at this step 2
Step 5 – Very Severe Asthma
- Daily high-dose ICS-LABA plus as-needed low-dose ICS-formoterol 1
- Add-on therapies based on phenotypic assessment:
Step 6 – Refractory Asthma
- High-dose ICS-LABA plus oral corticosteroids 2
- Continue biologic therapy for appropriate phenotypes 2
- Before initiating oral steroids, trial of leukotriene receptor antagonist, theophylline, or zileuton may be considered, though evidence is limited 2
Track 2 (Alternative): SABA as Reliever
Step 1 – Mild Intermittent Asthma
Step 2 – Mild Persistent Asthma
- Daily low-dose ICS plus as-needed SABA 2, 1
- Alternative (less effective) options: leukotriene receptor antagonist, cromolyn, nedocromil, or theophylline 2
Step 3 – Moderate Persistent Asthma
- Daily low-dose ICS-LABA plus as-needed SABA 2, 1
- Alternative: medium-dose ICS alone 2
- Alternative: low-dose ICS plus leukotriene receptor antagonist, theophylline, or zileuton 2
Step 4 – Severe Persistent Asthma
- Daily medium-dose ICS-LABA plus as-needed SABA 2, 1
- Alternative: medium-dose ICS plus leukotriene receptor antagonist, theophylline, or zileuton 2
- Specialist consultation recommended 2
Step 5 – Very Severe Asthma
- Daily high-dose ICS-LABA plus as-needed SABA 2, 1
- Add omalizumab for allergic asthma 2
- Add-on therapies as per Track 1 1
Step 6 – Refractory Asthma
- High-dose ICS-LABA plus oral corticosteroids plus as-needed SABA 2
- Continue omalizumab for allergic phenotypes 2
Pediatric Considerations (Ages 5-11 Years)
Step 1
- PRN SABA only 2
Step 2
- Daily low-dose ICS plus PRN SABA 2
- Alternative: leukotriene receptor antagonist, cromolyn, nedocromil, or theophylline 2
Step 3
- Daily medium-dose ICS plus PRN SABA (preferred for children <4 years due to lack of LABA safety data) 1
- Daily low-dose ICS-LABA plus PRN SABA (preferred for children ≥4 years) 2, 1
- Alternative: low-dose ICS plus leukotriene receptor antagonist or theophylline 2
Step 4
- Daily medium-dose ICS-LABA plus PRN SABA 2
- Alternative: medium-dose ICS plus leukotriene receptor antagonist or theophylline 2
Step 5
- Daily high-dose ICS-LABA plus PRN SABA 2
- Consider omalizumab for patients ≥12 years with allergic asthma 1
Step 6
- Daily high-dose ICS-LABA plus oral corticosteroids plus PRN SABA 2
Critical Safety Warnings
- LABA must never be prescribed as monotherapy due to increased risk of asthma-related mortality; always use in fixed-dose combination with ICS 2, 1
- SABA-only treatment carries significant risks including increased severe exacerbations and mortality 3
- Using SABA >2 days/week for symptom relief (excluding pre-exercise use) indicates inadequate control and necessitates stepping up therapy 2, 1, 5
- Montelukast carries an FDA Boxed Warning for neuropsychiatric events issued in March 2020 2
- Theophylline requires serum concentration monitoring due to narrow therapeutic index 2
- Zileuton requires liver function monitoring and has limited evidence as adjunctive therapy 2
When to Step Up Therapy
Immediate step-up is indicated after any severe exacerbation in the past 12 months. 1
Before stepping up, verify:
- Medication adherence 2, 1
- Correct inhaler technique (check at every visit) 2, 1
- Control of environmental triggers 2, 1
- Management of comorbidities 2
Step up if:
- SABA use >2 days/week for symptom relief 2, 1, 5
- Daytime symptoms >2 days/week 1
- Any nighttime awakenings 1
- Any activity limitation 1
- FEV₁ or peak flow <80% predicted 2, 1
When to Step Down Therapy
Step down when asthma is well-controlled for at least 3 consecutive months to find the minimum effective dose. 2, 1
Well-controlled asthma is defined by all of the following:
- Daytime symptoms ≤2 days/week 1
- No nighttime awakenings 1
- SABA use ≤2 days/week (excluding pre-exercise use) 1
- No activity limitation 1
- FEV₁ or peak flow ≥80% predicted 2, 1
Assessment and Monitoring
Control Assessment
Reassess control every 2-6 weeks after initiating or changing therapy, evaluating: 2
- Symptom frequency (day and night) 2
- SABA use frequency 2
- Activity limitation 2
- Lung function (FEV₁ or peak flow) 2
Risk Assessment
Assess risk factors at diagnosis and at least every 1-2 years: 1
- Medication-related: No ICS prescription, poor adherence, incorrect technique, high SABA use (>1 × 200-dose canister/month) 1
- Comorbidities: Obesity, chronic rhinosinusitis, GERD, food allergy, anxiety, depression 1
- Environmental exposures: Smoking, allergen exposure in sensitized individuals, air pollution 1
- Lung function: Low FEV₁ (especially <60% predicted), high reversibility 1
- Inflammatory markers: Sputum or blood eosinophilia, elevated FeNO 1
- History: Prior intubation/ICU admission, ≥1 severe exacerbation in past 12 months 1
Adjunctive Therapies
Allergen Immunotherapy
- Subcutaneous allergen immunotherapy (SCIT) can be considered at Steps 2-4 for allergic asthma 2, 1
- Strongest evidence for single-allergen extracts targeting house dust mite, animal dander, and pollens 2, 1
- Evidence is weak for mold and cockroach allergens 2, 1
- The role of allergy is greater in children than adults 1
Environmental Control
- Multi-component allergen-specific mitigation strategies are conditionally recommended for individuals with sensitization to identified indoor allergens 2
- Integrated pest management is conditionally recommended for individuals with sensitization to mice and cockroaches 2
- Impermeable pillow/mattress covers should only be used as part of a multi-component strategy, not as a single intervention 2
Common Pitfalls to Avoid
- Failing to recognize SABA overuse (>2 days/week) as a sign of inadequate control requiring step-up 2, 1, 5
- Prescribing LABA as monotherapy instead of fixed-dose combination with ICS 2, 1
- Not verifying inhaler technique before escalating therapy 2, 1
- Ignoring environmental triggers and comorbidities that contribute to poor control 2, 1
- Delaying specialist referral when patients reach Step 4 or higher 2
- Not performing phenotypic assessment (eosinophil count, allergen sensitization) before adding biologic therapy 1